The Development of Cellular Therapy for the Correction of CMV-Specific Immunodeficiency After Stem Cell Transplantation

Medicine & Life Sciences

1. T-Lymphocytes 100%
2. Cytomegalovirus 62%
3. Peptides 57%
4. Phosphopeptides 54%
5. Adoptive Transfer 41%
6. integrin alpha4beta7 41%
7. Adenoviridae 39%
8. Major Histocompatibility Complex 38%
9. Adoptive Immunotherapy 35%
10. HLA-A2 Antigen 34%
11. Stem Cell Transplantation 33%
12. Memory 31%
13. Minor Histocompatibility Antigens 30%
14. HIV 28%
15. Immune Reconstitution 26%
16. Tissue Donors 26%
17. Transformed Cell Line 26%
18. Transplants 24%
19. Histocompatibility Antigens Class I 24%
20. Cell- and Tissue-Based Therapy 22%
21. Human Herpesvirus 4 22%
22. Adiponectin 21%
23. Phenotype 21%
24. Salmonella 21%
25. Humoral Immunity 21%
26. Leukemia 20%
27. oxidized low density lipoprotein 20%
28. Epitopes 18%
29. Immunity 18%
30. Patient Selection 17%
31. Staining and Labeling 17%
32. Adenoviridae Infections 16%
33. Virus Diseases 16%
34. B-Lymphocytes 15%
35. Stem Cells 15%
36. Phosphorylation 14%
37. HLA Antigens 13%
38. Clone Cells 13%
39. Apolipoproteins B 11%
40. HIV Infections 9%
41. T-Cell Antigen Receptor 8%
42. Lipopolysaccharides 8%
43. Immunotherapy 8%
44. Hematopoietic Stem Cells 8%
45. Cell Line 8%
46. Phosphoproteins 8%
47. Antibodies 7%
48. Neoplasms 7%
49. Graft vs Host Disease 7%
50. Ligands 7%
51. Amino Acids 7%
52. Enzyme-Linked Immunospot Assay 6%
53. Antigens 6%
54. T-Lymphocyte Subsets 6%
55. Bacteremia 6%
56. Interferon-gamma 6%
57. Blood Donors 5%
58. Cellular Immunity 5%
59. Tumor Necrosis Factor Receptors 5%
60. Homeostasis 5%
61. Blood Cells 5%